Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 94, Issue 3, Pages 302-304Publisher
WILEY
DOI: 10.1038/clpt.2013.109
Keywords
-
Categories
Funding
- NIGMS NIH HHS [T32GM007019] Funding Source: Medline
Ask authors/readers for more resources
Understanding drug metabolism is essential for identifying drug-drug interactions (DDIs). As new data concerning a drug's pharmacokinetics arise, updates to drug labels and administration procedures should rapidly follow. However, the US Food and Drug Administration (FDA) has inconsistently updated drug labels, based on new research findings (i.e., in peer-reviewed publications). In this Commentary, we highlight recent findings on the metabolism of imatinib and argue for a more stringent protocol for updating drug labels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available